Johnson & Johnson
Moat Score — Johnson & Johnson
Total Moat Score
18 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 5 / 5 | J&J's moat rests on an exceptionally broad portfolio of patent-protected drugs and FDA-cleared devices, backed by one of the largest R&D budgets in healthcare and a AAA-rated balance sheet that few competitors can match. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 3 / 5 | Massive global scale in manufacturing and R&D, along with top-tier credit access, gives J&J cost and capital advantages over smaller single-segment pharma or device peers, though large rivals like Pfizer and Medtronic operate at comparable scale. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 4 / 5 | Patent-protected branded pharmaceuticals like Darzalex and Tremfya command premium pricing, though this power erodes sharply once exclusivity lapses, as seen with Stelara's ongoing biosimilar-driven decline. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Prescription drugs and medical devices are sold and used independently of how many other patients or providers use them; there is no network effect in J&J's business. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 3 / 5 | Physician prescribing habits and hospital surgical-device standardization (e.g., DePuy Synthes implants, Ethicon instruments) create meaningful switching friction, though generics and biosimilars can displace pharma revenue once patents expire. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 3 / 5 | The scale of R&D investment and regulatory approval required to compete across both pharma and medtech at J&J's breadth limits the field to a small set of global majors, though each individual therapeutic or device category still faces multiple well-capitalized competitors. |